Literature DB >> 17221180

Economic impact of shifting the locus of care for neuropathic pain from specialists to general practitioners.

Ariel Berger1, Piotr Kramarz, Gry Stine Kopperud, John Edelsberg, Gerry Oster.   

Abstract

We developed a decision-analytic model to examine the economic impact of shifting the locus of care for patients with painful neuropathies from specialists to GPs. The impetus for such a shift was assumed to be a formal education program, focusing on the recognition and treatment of neuropathic pain, conducted for GPs. In the model, all patients with neuropathic pain were assumed to initiate care with their GPs and then be referred to specialists and, ultimately, pain clinics as required for adequate pain control. Two alternative scenarios were examined--the "current" arrangement in which most patients were assumed to be referred for treatment by specialists and pain clinics and a "hypothetical" arrangement in which GPs were assumed to play an expanded role in the treatment of neuropathic pain and which, therefore, often precluded the need for referral. The model was populated with clinical, epidemiologic, and economic data from Norway. A total of 34,951 persons in Norway were estimated to seek care for painful neuropathies each year. The formal education program was assumed to cost 1.5 million Kroner (NOK). Shifting the locus of care from specialists to GPs would result in 4,715 additional GP visits, but 12,123 fewer specialist visits and 7,967 fewer visits to pain clinics. This change would result in estimated savings to the Norwegian health-care system in 2004 of 74.1 million NOK (approx. US $11.9 million). A partial shift in the locus of care of painful neuropathies from specialists to GPs may result in substantial cost savings to the Norwegian health-care system.

Entities:  

Mesh:

Year:  2007        PMID: 17221180     DOI: 10.1007/s10198-006-0025-2

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN: 1618-7598


  22 in total

1.  Rapid initiation of gabapentin: a randomized, controlled trial.

Authors:  R S Fisher; R C Sachdeo; J Pellock; P E Penovich; L Magnus; P Bernstein
Journal:  Neurology       Date:  2001-03-27       Impact factor: 9.910

2.  Opioid responsiveness of cancer pain syndromes caused by neuropathic or nociceptive mechanisms: a combined analysis of controlled, single-dose studies.

Authors:  N I Cherny; H T Thaler; H Friedlander-Klar; J Lapin; K M Foley; R Houde; R K Portenoy
Journal:  Neurology       Date:  1994-05       Impact factor: 9.910

3.  Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled, parallel-group study. The US Gabapentin Study Group No. 5.

Authors: 
Journal:  Neurology       Date:  1993-11       Impact factor: 9.910

4.  Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial.

Authors:  M Backonja; A Beydoun; K R Edwards; S L Schwartz; V Fonseca; M Hes; L LaMoreaux; E Garofalo
Journal:  JAMA       Date:  1998-12-02       Impact factor: 56.272

5.  Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial.

Authors:  M Rowbotham; N Harden; B Stacey; P Bernstein; L Magnus-Miller
Journal:  JAMA       Date:  1998-12-02       Impact factor: 56.272

6.  Association of pain relief with drug side effects in postherpetic neuralgia: a single-dose study of clonidine, codeine, ibuprofen, and placebo.

Authors:  M B Max; S C Schafer; M Culnane; R Dubner; R H Gracely
Journal:  Clin Pharmacol Ther       Date:  1988-04       Impact factor: 6.875

7.  Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain.

Authors:  S Arnér; B A Meyerson
Journal:  Pain       Date:  1988-04       Impact factor: 6.961

8.  Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia.

Authors:  C P Watson; N Babul
Journal:  Neurology       Date:  1998-06       Impact factor: 9.910

9.  Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy.

Authors:  Y Harati; C Gooch; M Swenson; S Edelman; D Greene; P Raskin; P Donofrio; D Cornblath; R Sachdeo; C O Siu; M Kamin
Journal:  Neurology       Date:  1998-06       Impact factor: 9.910

10.  Gabapentin versus lamotrigine monotherapy: a double-blind comparison in newly diagnosed epilepsy.

Authors:  Martin J Brodie; David W Chadwick; Henning Anhut; Andreas Otte; Silke-Lo Messmer; Stephen Maton; Wilhelm Sauermann; Guta Murray; Elizabeth A Garofalo
Journal:  Epilepsia       Date:  2002-09       Impact factor: 5.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.